Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708524 · ClinicalTrials.gov registry record · NA
Clinical Study of Approved and Investigational Contact Lenses
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 554
- Enrollment target
- 18
- Study locations
NCT02708524: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT02708524 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 554 participants, above the 112-participant average among 20 other Visual Acuity trials with a reported enrollment target (395% higher). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02708524, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 554 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a multi-site, 5-visit, double-masked, dispensing study comparing an investigational contact lens with currently-marketed contact lenses. The objective of the study is to evaluate the comfort of the lenses when worn for 30 (-2/+6) days on daily wear modality.
Primary Outcome
Subjective Overall Comfort was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more
Conditions Studied
Interventions
- DEVICE Senofilcon C Contact Lens
- DEVICE Comfilcon A Contact Lens
- DEVICE Lotrafilcon B Contact Lens
- DEVICE Samfilcon A Contact Lens
Study Locations (18)
Florida
- - Fruit Cove
- - Jacksonville
- - Jacksonville
- - Longwood
- - Tallahassee
- - Tampa
Alabama
- - Montgomery
Georgia
- - Roswell
Illinois
- - Bloomington
Michigan
- - East Lansing
Minnesota
- - Medina
New Jersey
- - Closter
New York
- - Vestal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-03 |
| Phase | NA |
What the finished NCT02708524 record still lists
NCT02708524 is an interventional study that assigns participants to a tested intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 20 other Visual Acuity trials with a reported enrollment target (395% higher).
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 4 interventions - of which Senofilcon C Contact Lens is the first listed.
NCT02708524 lists 18 locations in 13 states (Florida, Alabama, Georgia).
Frequently Asked Questions
What is clinical trial NCT02708524 about?
NCT02708524 is a clinical study titled "Clinical Study of Approved and Investigational Contact Lenses". This is a multi-site, 5-visit, double-masked, dispensing study comparing an investigational contact lens with currently-marketed contact lenses. The objective of the study is to evaluate the comfort of the lenses when worn for 30 (-2/+6) days on daily wear modality.
What is the current status of trial NCT02708524?
This trial is currently completed. It is a NA study. The enrollment target is 554 participants. The study started on 2016-01. Estimated completion is 2016-03.
What conditions does trial NCT02708524 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT02708524?
The interventions under investigation include: Senofilcon C Contact Lens (DEVICE), Comfilcon A Contact Lens (DEVICE), Lotrafilcon B Contact Lens (DEVICE), Samfilcon A Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT02708524?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02708524 being conducted?
This trial has 18 study locations across Alabama, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02708524's enrollment target sits among peer trials
554 1st of 20 higher than 20 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Effect of Scatter on Visual Performance
RECRUITING · NA
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Evaluation of Approved Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia